Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common stock, par value $0.00001
-
Shares outstanding
-
43.8M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
1.69M
-
Shares change
-
-188K
-
Total reported value, excl. options
-
$2.43M
-
Value change
-
-$324K
-
Number of buys
-
3
-
Number of sells
-
-7
-
Price
-
$1.43
Significant Holders of Cellectar Biosciences, Inc. - Common stock, par value $0.00001 (CLRB) as of Q1 2023
23 filings reported holding CLRB - Cellectar Biosciences, Inc. - Common stock, par value $0.00001 as of Q1 2023.
Cellectar Biosciences, Inc. - Common stock, par value $0.00001 (CLRB) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.69M shares
of 43.8M outstanding shares and own 3.87% of the company stock.
Largest 10 shareholders include AIGH Capital Management LLC (932K shares), Worth Venture Partners, LLC (337K shares), VANGUARD GROUP INC (175K shares), RENAISSANCE TECHNOLOGIES LLC (57.4K shares), BlackRock Inc. (57K shares), GEODE CAPITAL MANAGEMENT, LLC (47.2K shares), Maven Securities LTD (25K shares), STATE STREET CORP (15.7K shares), MORGAN STANLEY (15K shares), and Bank of New York Mellon Corp (12K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.